Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Short SellingSee which listed companies have disclosed short interest
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Optomed

1.41 EUR+0.57 %16/10 17:25
5,660 following

OPTOMED

NASDAQ Helsinki

Medical Equipment & Services

Health Care

Overview
Financials & Estimates
Dividend
Short Selling
Investor views
Compare
+0.57 %
-11.01 %
-14.06 %
-43.31 %
-62.71 %
-62.51 %
-49.88 %
-86.55 %
-69.30 %

Optomed operates in the medical technology sector. The company conducts research and development of specialized eye cameras. Development takes place of both hardware and software that are resold under different brands. Operations are held on a global level, with the largest presence in the Nordic market. Customers consist of research institutes and hospitals. The company has its headquarters in Oulu.

Read more
Market cap
30.22M EUR
Turnover
19.75K EUR
P/E (adj.) (26e)
-11.11
EV/EBIT (adj.) (26e)
-7.75
P/B (26e)
1.41
EV/S (26e)
1.44
Dividend yield-% (26e)
-
Coverage
Recommendation
Accumulate
Target price
2.00 EUR
Updated
2026-08-17
Disclaimer
Juha Kinnunen
Juha Kinnunen

Analyst

Latest research

Latest analysis report

Released: 2026-08-17

Revenue and EBIT-%
EPS and dividend
Financial calendar
Risk
Business risk
Valuation risk
Low
High
All
Research
Webcasts
Press releases
ShowingAll content types

Forum discussions
Oliko tämä aihe jo täällä? (Jos oli, saa poistaa). Wiser Asia postaus: China just made fundus screening a national target. On Sep 7, China NHS other authorities issued the 2026–2030 Eye Health Work Plan. Its core shift is blunt: from treating disease to managing health. For the first...
23 hours ago
by kivimies
16
Sure, this has been discussed here. At some point, there were tons of pictures of actual use in hospitals, nursing homes, everywhere you looked… and then typical radio silence… Hopefully it’s actually moving forward, because the potential is utterly insane Edit. Over there in China...
17 hours ago
by Mr. Stock
14
Doesn’t Eyenuk use Optomed’s cameras with their own AI in Canada? At least the CEO is really hyping up the handhelds… LinkedIn #diabetes #fnhma #eyeart #fnhma2026 #firstnationshealth #diabeticretinopathy... Eye screening for people living with #diabetes shouldn't depend on how far...
yesterday
by Mr. Stock
9
The problem with these sales directors and other strategic guys is that the starting salary in the US is half a million, and once you get a good one, they bring 4–5 of their own buddies through the door with them, and just like that, you have a team costing two million a year before...
10/15/2026, 2:31 PM
by Dr.Feelgood
9
As long as the financing risk remains even theoretical, the stock price will just drift sideways. As soon as that risk disappears after 2–3 quarters of solid track record, it will take off like a rocket. All that’s needed here is patience—it really is that simple.
13 hours ago
by marmot76
8
A bit of investigative journalism in between: apparently an Implementation & Customer Success Coordinator joined the AEYE Health organization recently (3 months ago): Recently hired by AEYE Health https://www.linkedin.com/in/natasha-rodriguez33/ And by the way, this Implementation...
10/15/2026, 7:26 PM
by Mr. Stock
8
Weekend reflections: is it really possible that the market is only looking at Optomed’s declining top line, even though the numbers tell a completely different story under the hood? Devices revenue dropped 15% currency-adjusted in Q2, but the CEO noted in an interview that camera...
13 hours ago
by Mr. Stock
4
Read more on our forum
Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
6/11
2026

Interim report Q3'26

18/2
2027

Annual report '26

4/5
2027

Interim report Q1'27

Regulatory press release2026-10-07 13:00

Optomed Oyj: Disclosure under Chapter 9, Section 10 of the Securities Markets Act regarding change in holdings

Optomed
Regulatory press release2026-09-28 15:17

Optomed Oyj - Managers' Transactions - Piila

Optomed
Regulatory press release2026-09-28 15:15

Optomed Oyj - Managers' Transactions - Piila

Optomed

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release2026-09-28 15:15

Optomed Oyj - Managers' Transactions - Piila

Optomed
Regulatory press release2026-09-28 15:15

Optomed Oyj - Managers' Transactions - Piila

Optomed
Regulatory press release2026-09-28 15:12

Optomed Oyj - Managers' Transactions - Myllylä

Optomed
Regulatory press release2026-09-28 15:10

Optomed Oyj - Managers' Transactions - Myllylä

Optomed
Regulatory press release2026-09-28 15:10

Optomed Oyj - Managers' Transactions - Myllylä

Optomed
Regulatory press release2026-09-28 15:10

Optomed Oyj - Managers' Transactions - Myllylä

Optomed
Regulatory press release2026-09-28 15:07

Optomed Oyj - Managers' Transactions - Knuutti

Optomed
Regulatory press release2026-09-28 15:05

Optomed Oyj - Managers' Transactions - Knuutti

Optomed
Regulatory press release2026-09-28 15:05

Optomed Oyj - Managers' Transactions - Knuutti

Optomed
Regulatory press release2026-09-28 15:05

Optomed Oyj - Managers' Transactions - Knuutti

Optomed
Regulatory press release2026-09-28 15:01

Optomed Oyj - Managers' Transactions - Himberg

Optomed
Regulatory press release2026-09-28 15:00

Optomed Oyj - Managers' Transactions - Himberg

Optomed
Regulatory press release2026-09-28 15:00

Optomed Oyj - Managers' Transactions - Himberg

Optomed
Regulatory press release2026-09-28 15:00

Optomed Oyj - Managers' Transactions - Himberg

Optomed
Regulatory press release2026-09-25 14:30

Optomed Oyj: Optomed's Board of Directors has resolved to establish a new stock option plan

Optomed
Optomeds dotterbolag Ubetec vann Veikkauchs anbudsförfarande
Analyst Comment2026-09-07 06:55 by
Juha Kinnunen

Optomeds dotterbolag Ubetec vann Veikkauchs anbudsförfarande

Veikkaus avtalstilldelning på 0,9 MEUR stärker dotterbolaget Ubetecs position på den finländska spelmarknaden som håller på att öppnas upp.

Optomed
Regulatory press release2026-09-04 14:00

Optomed Oyj: Composition of Optomed's Shareholders' Nomination Board

Optomed